Jefferies Financial Group Reiterates “Buy” Rating for Indivior (LON:INDV)

Indivior (LON:INDV)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a report released on Tuesday, MarketBeat Ratings reports. They currently have a GBX 1,800 ($22.63) target price on the specialty pharmaceutical company’s stock. Jefferies Financial Group’s target price suggests a potential upside of 90.38% from the stock’s previous close.

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,500 ($18.86) price target on shares of Indivior in a research note on Thursday, September 5th.

Indivior Trading Up 1.6 %

INDV stock opened at GBX 945.50 ($11.89) on Tuesday. The company has a market capitalization of £1.22 billion, a PE ratio of -1,181.88, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The company has a debt-to-equity ratio of 2,790.00, a quick ratio of 1.52 and a current ratio of 0.85. Indivior has a one year low of GBX 554.50 ($6.97) and a one year high of GBX 1,770 ($22.25). The company’s 50 day moving average price is GBX 771.78 and its two-hundred day moving average price is GBX 920.82.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.